Chong Kun Dang Pharmaceutical : Decision on Entering into Trust Contract for Acquisition of Treasury Stock
February 14, 2022 at 01:02 am
Share
Decision on Entering into Trust Contract for Acquisition of Treasury Stock
1. Contract amount (KRW)
10,000,000,000
2. Contract period
Start date
2022-02-11
End date
2023-02-10
3. Purpose of contract
To stabilize share price and enhance shareholder value
4. Counterparty (trust company)
KB Securities Co., Ltd.
5. Scheduled contract date
2022-02-11
6. Treasury stock holdings before contract
Acquisition within profits available for dividends (shrs.)
Common stock
204,884
Ratio (%)
1.7
Different classes of stocks
-
Ratio (%)
-
Acquisition for other reasons (shrs.)
Common stock
47,773
Ratio (%)
0.4
Different classes of stocks
-
Ratio (%)
-
7. Date of board resolution (decision date)
2022-02-10
- Attendance of outside directors
Present (No.)
2
Absent (No.)
-
- Attendance of auditors (members of Audit Committee who are not outside directors)
Present
8. Entrusted brokerage company
KB Securities Co., Ltd.
9. Other matters to be factored into investment decisions
-
【Limit to Acquiring Treasury Stocks】
Category
Amount (KRW)
1. Limit to "profits available for dividends" in the Commercial Act as of the immediately preceding business year end
ⓐ. Net assets
548,478,542,387
ⓑ. Amount of capital
27,214,212,500
ⓒ. Total amount of capital reserve and earned surplus reserves accumulated up to preceding business year
273,091,083,515
ⓓ. Unrealized gain as prescribed by Presidential Decree
14,358,455,328
Sub total (ⓐ-ⓑ-ⓒ-ⓓ)
233,814,791,044
2. Acquired amount of treasury stock after previous fiscal year end
3,823,634,640
3. Amount of 'dividends' and related 'earned profit reserve' decided at annual general meeting of shareholders after previous fiscal year end
11,908,292,000
4. Amount of 'interim/quarterly dividends' and related 'earned profit reserves' decided by board of directors after previous fiscal year end
-
5. Amount of trust contract
20,000,000,000
6. Acquisition cost of treasury stock sold after previous fiscal year end (moving average method)
-
Limit to acquisition of treasury stock (1-2-3-4-5+6)
198,082,864,404
【Holding Amount of Treasury Stock before Decision to Enter into Trust Contract】
(in shrs.)
Methods of acquisition
Type of stocks
Beginning balance
Change
Closing balance
Remarks
Acquisition (+)
Disposal (-)
Share retirement (-)
Amount of stocks acquired within profits available for dividends
Direct acquisition
Direct acquisition in exchange
Common stock
49,300
-
-
-
49,300
-
Different classes of stocks
-
-
-
-
-
-
Direct acquisition in OTC
Common stock
-
-
-
-
-
-
Different classes of stocks
-
-
-
-
-
-
Tender offer
Common stock
-
-
-
-
-
-
Different classes of stocks
-
-
-
-
-
-
Sub total (a)
Common stock
49,300
-
-
-
49,300
-
Different classes of stocks
-
-
-
-
-
-
Acquisition by trust contract
Number of stocks indirectly held through trust contracts
Common stock
110,665
44,919
-
-
155,584
-
Different classes of stocks
-
-
-
-
-
-
Number of stocks directly held
Common stock
-
-
-
-
-
-
Different classes of stocks
-
-
-
-
-
-
Sub total (b)
Common stock
110,665
44,919
-
-
155,584
-
Different classes of stocks
-
-
-
-
-
-
Amount of stocks acquired for other reasons (c)
Common stock
27,337
20,436
-
-
47,773
Purchase of fraction shares following the Company's split-off and capital increase without consideration
Different classes of stocks
-
-
-
-
-
-
Total (a+b+c)
Common stock
187,302
65,355
-
-
252,657
-
Different classes of stocks
-
-
-
-
-
-
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chong Kun Dang Pharmaceutical Corporation published this content on 14 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 February 2022 01:01:03 UTC.
Chong Kun Dang Pharmaceutical Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The company sells products in domestic and overseas markets.